Jianzhong Ai1,2,3, Phillip W L Tai2, Yi Lu2,4, Jia Li2, Hong Ma2, Qin Su2, Qiang Wei1, Hong Li1, Guangping Gao2,3,5. 1. Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China. 2. Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts. 3. Department of Microbiology and Physiology Systems, University of Massachusetts Medical School, Worcester, Massachusetts. 4. Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, P.R. China. 5. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China.
Abstract
BACKGROUND: Prostate diseases are common in males worldwide with high morbidity. Gene therapy is an attractive therapeutic strategy for prostate diseases, however, it is currently underdeveloped. As well known, adeno virus (Ad) is the most widely used gene therapy vector. The aims of this study are to explore transduction efficiency of Ad in prostate cancer cells and normal prostate tissue, thus further providing guidance for future prostate pathophysiological studies and therapeutic development of prostate diseases. METHODS: We produced Ad expressing enhanced green fluorescence protein (EGFP), and characterized the transduction efficiency of Ad in both human and mouse prostate cancer cell lines in vitro, as well as prostate tumor xenograft, and wild-type mouse prostate tissue in vivo. Ad transduction efficiency was determined by EGFP fluorescence using microscopy and flow cytometry. Cell type-specific transduction was examined by immunofluorescence staining of cell markers. RESULTS: Our data showed that Ad efficiently transduced human and mouse prostate cancer cells in vitro in a dose dependent manner. Following intratumoral and intraprostate injection, Ad could efficiently transduce prostate tumor xenograft and the major prostatic cell types in vivo, respectively. CONCLUSIONS: Our findings suggest that Ad can efficiently transduce prostate tumor cells in vitro as well as xenograft and normal prostate tissue in vivo, and further indicate that Ad could be a potentially powerful toolbox for future gene therapy of prostate diseases.
BACKGROUND:Prostate diseases are common in males worldwide with high morbidity. Gene therapy is an attractive therapeutic strategy for prostate diseases, however, it is currently underdeveloped. As well known, adeno virus (Ad) is the most widely used gene therapy vector. The aims of this study are to explore transduction efficiency of Ad in prostate cancer cells and normal prostate tissue, thus further providing guidance for future prostate pathophysiological studies and therapeutic development of prostate diseases. METHODS: We produced Ad expressing enhanced green fluorescence protein (EGFP), and characterized the transduction efficiency of Ad in both human and mouseprostate cancer cell lines in vitro, as well as prostate tumor xenograft, and wild-type mouse prostate tissue in vivo. Ad transduction efficiency was determined by EGFP fluorescence using microscopy and flow cytometry. Cell type-specific transduction was examined by immunofluorescence staining of cell markers. RESULTS: Our data showed that Ad efficiently transduced human and mouseprostate cancer cells in vitro in a dose dependent manner. Following intratumoral and intraprostate injection, Ad could efficiently transduce prostate tumor xenograft and the major prostatic cell types in vivo, respectively. CONCLUSIONS: Our findings suggest that Ad can efficiently transduce prostate tumor cells in vitro as well as xenograft and normal prostate tissue in vivo, and further indicate that Ad could be a potentially powerful toolbox for future gene therapy of prostate diseases.
Authors: Thomas C Fenter; Michael James Naslund; Manan B Shah; Michael T Eaddy; Libby Black Journal: Am J Manag Care Date: 2006-03 Impact factor: 2.229
Authors: Martin C S Wong; William B Goggins; Harry H X Wang; Franklin D H Fung; Colette Leung; Samuel Y S Wong; Chi Fai Ng; Joseph J Y Sung Journal: Eur Urol Date: 2016-06-08 Impact factor: 20.096